市場調查報告書
商品編碼
1229656
藥物釋放型血管支架的全球市場:規模,佔有率,COVID-19影響分析(2023年~2029年):MedCoreDrug-Eluting Stent Market Size, Share, & COVID-19 Impact Analysis | Global | 2023-2029 | MedCore |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球藥物釋放型血管支架的市場規模在2022年估算為1億560萬美金。該市場在預測期間內預計將以1.8%的年複合成長率擴大,並達到1億1,960萬美元。
本報告提供全球藥物釋放型血管支架市場相關調查,提供市場概要,以及各市場區隔,各地區趨勢,競爭情形等資訊。
The global market for drug-eluting stents had a valuation of $105.6 million in 2022, and it is projected to grow at a CAGR of 1.8% during the forecast period, reaching $119.6 million. The comprehensive report on the market focuses solely on drug-eluting stents and does not include its extended set.
The primary driver of the drug-eluting stent market is the lack of competition. Intersect ENT is the sole competitor in the market, which enables the company to maintain higher selling prices, driving up the market value. The company's monopoly on the market is a significant factor in the growth of the drug-eluting stent market.
The Global drug-eluting stent market was led by Intersect ENT.
Intersect ENT dominates the drug-eluting stent market with its Propel® family of products. These stents are designed to be used in combination with ethmoid sinus surgery, with different shapes and sizes available to suit different sinus anatomies. The company's product line also includes Sinuva® Sinus Implant, which is used to treat nasal polyps in patients who have undergone previous ethmoid sinus surgery. Both Propel® and Sinuva® implants release the corticosteroid mometasone furoate.
ENT Drug-Eluting Stent Market - MedCore
Read more about iData's 9-Step Research Methodology.